Trial Profile
Assessment of Clinical Outcome and Treatment Quality Under Adequate Use of Tolvaptan In Correction of Hyponatremia in Patients Hospitalized With Worsening Heart Failure and Hyponatremia
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Tolvaptan (Primary)
- Indications Hyponatraemia
- Focus Pharmacokinetics
- Acronyms AQUATIC
- Sponsors Korea Otsuka Pharmaceutical
- 12 Jun 2017 Status changed from recruiting to discontinued.
- 12 Jun 2017 Status changed from recruiting to discontinued.
- 29 Nov 2016 Planned End Date changed from 1 Apr 2016 to 1 May 2017.